[go: up one dir, main page]

CA2147598A1 - Morphogenese induite par op-3 - Google Patents

Morphogenese induite par op-3

Info

Publication number
CA2147598A1
CA2147598A1 CA002147598A CA2147598A CA2147598A1 CA 2147598 A1 CA2147598 A1 CA 2147598A1 CA 002147598 A CA002147598 A CA 002147598A CA 2147598 A CA2147598 A CA 2147598A CA 2147598 A1 CA2147598 A1 CA 2147598A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
tissue
protein
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002147598A
Other languages
English (en)
Inventor
Hermann Oppermann
Engin Ozkaynak
Thangavel Kuberasampath
David C. Rueger
Roy H. L. Pang
Charles M. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2147598A1 publication Critical patent/CA2147598A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002147598A 1992-11-03 1993-11-02 Morphogenese induite par op-3 Abandoned CA2147598A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97109192A 1992-11-03 1992-11-03
US971,091 1992-11-03
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31

Publications (1)

Publication Number Publication Date
CA2147598A1 true CA2147598A1 (fr) 1994-05-11

Family

ID=27363460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002147598A Abandoned CA2147598A1 (fr) 1992-11-03 1993-11-02 Morphogenese induite par op-3

Country Status (5)

Country Link
EP (1) EP0672064A1 (fr)
JP (1) JPH08503198A (fr)
AU (1) AU681362B2 (fr)
CA (1) CA2147598A1 (fr)
WO (1) WO1994010203A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972703A (en) * 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998034655A1 (fr) † 1997-02-07 1998-08-13 Stryker Corporation Dispositif osteogeniques sans matrice, implants et methodes d'utilisation associees
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
WO1998050060A1 (fr) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies contre l'insuffisance renale aigue
US20030032586A1 (en) * 1997-05-15 2003-02-13 David C. Rueger Compositions for morphogen-induced osteogenesis
WO1998054572A1 (fr) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Procedes pour evaluer la morphogenese des tissus et leur activite
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
CA2558395C (fr) 2004-03-10 2011-11-29 Scil Technology Gmbh Implants revetus, fabrication et utilisation de ceux-ci
JP5201987B2 (ja) 2004-05-25 2013-06-05 ストライカー コーポレイション 軟骨欠損を処置するための、形態形成タンパク質の使用
CA2652549A1 (fr) 2006-05-17 2007-12-13 Stryker Corporation Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (fr) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Formules protéiniques comprenant le facteur gdf-5 dans une solution aqueuse acide
AU2009214629A1 (en) 2008-02-13 2009-08-20 Eric T. Choi BMP-7 for use in treating vascular sclerosis
US7947649B2 (en) 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
CN102369016A (zh) 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
US20100204124A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
WO2010110974A1 (fr) 2009-03-24 2010-09-30 Stryker Corporation Procédés et compositions pour l'ingénierie tissulaire
WO2011031856A1 (fr) 2009-09-09 2011-03-17 Stryker Corporation Bmp-7 à utiliser dans le traitement de la douleur induite par les lésions et les maladies d'articulation
CA2774024A1 (fr) 2009-09-17 2011-03-24 Stryker Corporation Tampons utilises pour la regulation du ph des proteines morphogenetiques osseuses
WO2011087768A1 (fr) 2009-12-22 2011-07-21 Stryker Corporation Variants de la bmp-7 dotés d'une immunogénicité réduite
ITMI20112437A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Uso di citochine, fattori di crescita e fattori antibatterici come materiale di sottofondo di cavita' per la terapia della carie penetrante dei denti e dell'infiammazione pulpare
EP3173087A1 (fr) * 2011-12-30 2017-05-31 Innomed S.A. Combinaison de facteurs de croissance, cytokines, facteurs antibactériens/antiviraux, facteurs de stimulation de cellules souches, protéines de complément c3a/c4a et facteurs chimiotactiques
EP2797609B1 (fr) 2011-12-30 2016-10-05 Innomed S.A. Combinaison de facteurs de croissance, de cytokines, de facteurs antibactériens/antiviraux, de facteurs de stimulation de cellules souches, de protéines du complément c3a/c4a, d'immunoglobulines et de facteurs chimiotactiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1225225A3 (fr) * 1988-04-08 2003-01-08 Stryker Corporation Dispositifs ostéogéniques
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5011961A (en) * 1990-06-13 1991-04-30 Dow Corning Limited Method of making organosilbutadiyne polymers
ATE203166T1 (de) * 1991-03-11 2001-08-15 Curis Inc Protein-induzierende morphogenese
EP0601135B1 (fr) * 1991-08-30 2005-11-02 Curis, Inc. Proteines osteogeniques pour le traitement des maladies osseuses metaboliques
WO1994003600A1 (fr) * 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Complexe soluble de proteines morphogeniques et sa composition

Also Published As

Publication number Publication date
AU5590094A (en) 1994-05-24
WO1994010203A3 (fr) 1994-08-18
EP0672064A1 (fr) 1995-09-20
WO1994010203A2 (fr) 1994-05-11
JPH08503198A (ja) 1996-04-09
AU681362B2 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
AU681362B2 (en) OP-3-induced morphogenesis
AU660019B2 (en) Protein-induced morphogenesis
EP0653942B1 (fr) Regeneration et reparation du systeme nerveux induites par morphogene
US5854071A (en) OP-3- induced morphongenesis
US6565843B1 (en) Protein-induced tissue morphogenesis
EP0646022B1 (fr) Protheses a proprietes osteogenes accrues
US5674844A (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6800603B2 (en) Morphogen-induced neural cell adhesion
US5652118A (en) Nucleic acid encoding a novel morphogenic protein, OP-3
US6949505B1 (en) Morphogen-induced dendritic growth
EP0661987B1 (fr) Regeneration du foie induite par des morphogenes
US6495513B1 (en) Morphogen-enhanced survival and repair of neural cells
WO1992007004A1 (fr) Proteine osteogenique
US6211146B1 (en) 60A protein-induced morphogenesis
WO1994006447A2 (fr) Morphogenese induite par la proteine 60a

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued